



ASX ANNOUNCEMENT

Additional Information Regarding Agreements with Hologic

MELBOURNE, Australia (16 January 2024) – Lumos Diagnostics Holdings Ltd (ASX: LDX), (“Lumos” or the “Company”) a leader in rapid, point-of-care (POC) diagnostic technologies, is pleased to provide the following additional information, as requested by the ASX, on its announcement “*Lumos Signs Major Development and IP Agreements with Hologic*” that was released to the ASX on 11 January 2024.

1. Details of the development milestones.

The body of work to be conducted under the Development Agreement, and payment profile, has been broken down into three phases:

- 1) Product Definition and Planning - define the parameters for the product and establish a project plan US\$0.4 million;
- 2) Assay Feasibility - conduct work to demonstrate the assay is able to detect the biomarkers US\$0.6 million; and
- 3) System Prototype Delivery – deliver a working prototype of the system - US\$3.7 million providing total milestone payments of up to US\$4.7 million.

These phases are elements of a standard diagnostic product development program in which Lumos has expertise and an established track record, and builds upon previous development work that Lumos has conducted for Hologic on the same product.

2. Expected costs associated with the Agreements.

The Intellectual Property Agreement is a license agreement to access intellectual property owned by Lumos and consequently does not have any costs associated with it. The costs associated with the Development Agreement relate to the cost of labor provided by Lumos staff, materials involved in the development work and an allocation for overheads. These costs are expected to be in line with typical costs associated with product development activities conducted by Contract Development and Manufacturing Organizations (CDMO) in the medical device industry.

3. Term/length of the Agreements.

The term of the license of the Intellectual Property agreement is determined by the expiry of existing and any new patents covering the intellectual property included in the agreement. The Development Agreement will commence on the Effective Date and shall remain in effect until all Development Activities

have been completed. As stated in the ASX announcement, Lumos expects to complete all the Development Activities contemplated in the Development Agreement within an 18-24 month timeframe.

4. Any other material terms including termination provisions.

Other material terms in the Development Agreement are consistent with standard medical device development contracts and allow Termination for Insolvency, Breach, and Lack of Identification of Critical Requirements.

-Ends-

This announcement has been approved by the Lumos Disclosure Committee.

About Lumos Diagnostics

Lumos Diagnostics specializes in rapid, cost-effective, and complete point-of-care (POC) diagnostic test technology to help healthcare professionals more accurately diagnose and manage medical conditions. Lumos offers customized assay development and manufacturing services for POC tests and proprietary digital reader platforms. Lumos also directly develops, manufactures, and commercializes novel Lumos-branded POC tests that target infectious and inflammatory diseases.

For more information visit lumosdiagnostics.com.

Forward-Looking Statements

This announcement contains forward-looking statements, including references to forecasts. Forward-looking statements are not guarantees of future performance and involve known and unknown risks, uncertainties, assumptions, and other important factors, many of which are beyond Lumos' control and speak only as of the date of this announcement. Readers are cautioned not to place undue reliance on forward-looking statements.

Media Contact:

Haley Chatres – Australia

HACK Director

haley@hck.digital

+61 (0) 423 139 163

Investor Contact:

Barrie Lambert

Chief Financial Officer, Lumos Diagnostics

ir@lumosdiagnostics.com

+61 3 9087 1598

Company Registered Office:

Lumos Diagnostics Holdings Ltd
Level 4, 100 Albert Rd
South Melbourne, VIC 3205
+61 3 9087 1598